$71.73
1.04% today
NYSE, Apr 01, 06:45 pm CET
ISIN
US28176E1082
Symbol
EW

Edwards Lifesciences Stock price

$72.48
+0.86 1.20% 1M
+6.49 9.83% 6M
-1.55 2.09% YTD
-21.77 23.10% 1Y
-45.24 38.43% 3Y
+9.61 15.28% 5Y
+48.74 205.27% 10Y
NYSE, Closing price Mon, Mar 31 2025
+1.57 2.21%
ISIN
US28176E1082
Symbol
EW
Sector

Key metrics

Market capitalization $42.46b
Enterprise Value $39.24b
P/E (TTM) P/E ratio 29.59
EV/FCF (TTM) EV/FCF 135.36
EV/Sales (TTM) EV/Sales 6.86
P/S ratio (TTM) P/S ratio 7.42
P/B ratio (TTM) P/B ratio 4.27
Revenue growth (TTM) Revenue growth -4.67%
Revenue (TTM) Revenue $5.72b
EBIT (operating result TTM) EBIT $1.53b
Free Cash Flow (TTM) Free Cash Flow $289.90m
Cash position $3.98b
EPS (TTM) EPS $2.45
P/E forward 30.18
P/S forward 7.30
EV/Sales forward 6.75
Short interest 1.62%
Show more

Is Edwards Lifesciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Edwards Lifesciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

32 Analysts have issued a Edwards Lifesciences forecast:

14x Buy
44%
17x Hold
53%
1x Sell
3%

Analyst Opinions

32 Analysts have issued a Edwards Lifesciences forecast:

Buy
44%
Hold
53%
Sell
3%

Financial data from Edwards Lifesciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
5,724 5,724
5% 5%
100%
- Direct Costs 1,262 1,262
12% 12%
22%
4,463 4,463
2% 2%
78%
- Selling and Administrative Expenses 1,698 1,698
2% 2%
30%
- Research and Development Expense 1,082 1,082
1% 1%
19%
1,682 1,682
8% 8%
29%
- Depreciation and Amortization 155 155
2% 2%
3%
EBIT (Operating Income) EBIT 1,527 1,527
9% 9%
27%
Net Profit 1,467 1,467
5% 5%
26%

In millions USD.

Don't miss a Thing! We will send you all news about Edwards Lifesciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Edwards Lifesciences Stock News

Neutral
Business Wire
about 23 hours ago
CHICAGO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new scientific evidence presented and published during the American College of Cardiology's (ACC) Annual Scientific Session & Expo, addressing the critical needs of patients with structural heart disease. Without treatment, 1 in 10 patients experiencing symptoms of severe aortic stenosis (AS) may die within five weeks. Ho...
Positive
Seeking Alpha
10 days ago
Health Care and Energy sectors outperform in 2025, with the Health Care Select Sector SPDR Fund ETF up 7% YTD, while Edwards Lifesciences lags. Despite a solid Q4 earnings beat, EW's shares remain undervalued with a reduced P/E multiple of 33x, yielding a price target of $84. Key risks include slower TAVR growth in Japan and hospital demand uncertainties, but long-term sales growth targets rema...
Neutral
Business Wire
26 days ago
SUNNYVALE, Calif.--(BUSINESS WIRE)--Intuitive Ventures today announced the appointment of Terri Burke, former head medtech investments at Epidarex Capital and a seasoned operator, as Senior Partner and Dr. Ross Jaffe, a co-founder of Versant Ventures, as Venture Advisor. Both medtech veterans, they will help support the continued growth of Intuitive Ventures in investing in start-ups reimaginin...
More Edwards Lifesciences News

Company Profile

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. Its portfolio includes technologies designed for nonsurgical replacement of heart valves. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring system measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Head office United States
CEO Bernard Zovighian
Employees 15,800
Founded 1958
Website www.edwards.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today